U.S. pharmacists can now prescribe Pfizer’s COVID-19 pill to at-risk people, FDA says

The U.S. Food and Drug Administration said on Wednesday it authorized state-licensed pharmacists to prescribe Pfizer Inc’s PFE.N COVID-19 pill, Paxlovid, to eligible patients.

Use of the pill, authorized to treat newly infected, at-risk people to prevent severe illness, has jumped in recent weeks as infections rise.

“Since Paxlovid must be taken within five days after symptoms begin, authorizing state-licensed pharmacists to prescribe Paxlovid could expand access to timely treatment for some patients,” Patrizia Cavazzoni, director for the FDA’s Center for Drug Evaluation and Research, said in a statement.

0:32 Canada working closely with Moderna, Pfizer on COVID-19 vaccines targeting Omicron subvariants: Duclos

The agency said patients who have tested positive for COVID-19 should bring their health records for the pharmacists to review for kidney and liver problems.

The agency said that pharmacists should refer the patients to a healthcare professional licensed to prescribe drugs if there is not sufficient information to assess kidney or liver function, or if modifications are needed due to a potential drug interaction.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.

Sign up for weekly health newsletter Sign Up

By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

The patients should also provide a list of medicines they are currently taking so their pharmacist can screen for drugs that can potentially react with Paxlovid, the FDA said.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)